Highest-materiality recent filing
Product revenue $82.5M, up 43% YoY; total revenue $83.1M, up 38%. Net income $2.2M vs net loss $9.2M.
Q4 total revenue $85.8M (+42.8% YoY); net income $11.1M vs net loss $5.1M in Q4 2024.
Xeris expects record 2025 revenue of $292M, up 44% YoY; beats guidance
Preliminary full-year 2025 total revenue of $292M, exceeding $285-290M guidance range, reflecting 44% YoY growth.
Xeris Biopharma receives USPTO Notice of Allowance for XP-8121 patent application
Patent allowance covers XP-8121 formulation for hypothyroidism, a novel product candidate.
Xeris Q3 product revenue $74M (+40% YoY); raises FY2025 guidance to $285-290M
Total product revenue $74.1M, up 40% YoY; total revenue $74.4M (+37% YoY).
Xeris Biopharma Q2 revenue up 49% to $71.5M; Recorlev +136%; raises FY guidance to $280-290M
Total revenue $71.5M (+49% YoY); net loss narrowed to $1.9M ($0.01/sh) from $15M ($0.10/sh).
Xeris unveils long-range strategy; targets ~$750M revenue by 2030
Reaffirms 2025 total revenue guidance of $260-$275M and commitment to adjusted EBITDA positivity.
Xeris Q1 revenue up 48% to $60.1M; Recorlev surges 141%; tightens FY guidance to $260-275M
Total revenue $60.1M (+48% YoY); net loss $9.2M ($0.06 loss per share) vs prior year loss.
Xeris Biopharma reports record Q4 revenue $60M (+35% YoY); guides 2025 rev $255M-$275M
Record Q4 total revenue $60.1M (+35% YoY); full-year $203.1M (+24% YoY)
Total FY2024 revenue expected at $203M, exceeding prior guidance of $198-202M (24% YoY growth).
Xeris Q3 total revenue $54.3M record; guides FY to $198-$202M
Product revenue $52.9M (+27% YoY); Gvoke $22.9M (+29%), Recorlev $17.7M (+119%), Keveyis $12.2M (-23%).
Total revenue of $48.1M (+26% YoY); product revenue record $46.5M.
Xeris Biopharma promotes Kevin McCulloch to President and COO
Kevin McCulloch, former Chief Commercial Officer, was promoted to President and COO effective August 1, 2024.
Xeris CEO Paul Edick steps down; John Shannon named CEO; Q2 revenue >$47M (+23% YoY)
CEO Paul R. Edick transitions to Senior Advisor effective Aug 1, 2024; John Shannon (President & COO) appointed new CEO and Board member.
Xeris Biopharma Q1 total revenue $40.6M (+22% YoY); tightens FY 2024 guidance to $175M-$200M
Net product revenue $40.3M (+24.8% YoY); Recorlev revenue $10.6M (+136.7%).
Xeris reports Q4 total revenue $44.4M (+34% YoY); refinances debt with $200M Hayfin facility
Q4 total revenue $44.4M, +34% YoY; full-year 2023 revenue $163.9M, +49% YoY.
On March 28, 2025, Ms. Ricki Fairley, a director of Xeris Biopharma Holdings, Inc. (the “Company”), notified the Company of her decision to resign from the Board of Directors (the “Board”) of the Company, effective as of March 28, 2025.
On March 28, 2025, the Board appointed Mr. James Brady to the Company’s Board, effective on such date.
On March 28, 2025, Mr. John Schmid informed the Board of his decision to not stand for reelection as a director at the Company’s 2025 annual meeting of stockholders (the “2025 Annual Meeting”).
On February 24, 2025, Mr. Ken Johnson, Pharm.D. notified Xeris Biopharma Holdings, Inc. (the “Company”) of his decision to retire as Senior Vice President, Global Development and Medical Affairs, effective as of April 1, 2025.
The Board of Directors of Xeris Biopharma Holdings, Inc. (the “Company”) promoted Kevin McCulloch to be President and Chief Operating Officer of the Company, effective as of August 1, 2024.
On July 8, 2024, the Company announced that, effective August 1, 2024 (the “Transition Date”), Paul R. Edick will transition from his role as Chief Executive Officer and Chairman of the Board of Directors of the Company (the “Board”) and will become a Senior Advisor to the Company.
The Board also approved the appointment of Mr. Shannon as a Class III director, effective as of the Transition Date.
On July 8, 2024, the Company announced that, effective August 1, 2024 (the “Transition Date”), Paul R. Edick will transition from his role as Chief Executive Officer and Chairman of the Board of Directors of the Company (the “Board”) and will become a Senior Advisor to the Company.
Marla S. Persky, currently a Class III director of the Company, has been appointed by the Board to serve as the Chairperson of the Board, effective as of the Transition Date.
John Shannon, currently the Company’s President and Chief Operating Officer, has been appointed by the Board to serve as the Company’s Chief Executive Officer, effective as of the Transition Date.
Max materiality 0.85 · Median 0.75 · Most common event earnings